AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Ovarian Neoplasms Clinical Trial

Official title:

An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05617755
• Other study ID #: AB-1015-101
• Status: Recruiting
• Phase: Phase 1
• Start date: November 29, 2022
• Est. completion date: February 2027

Study information

• Verified date: May 2024
• Source: Arsenal Biosciences, Inc.
• Contact: Arsenal Biosciences
• Phone: 650-446-4874
• Email: clinicaltrials[@]arsenalbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.

Description:

This study is intended for the patients who have been diagnosed with Epithelial Ovarian Cancer that either came back or did not improve after platinum treatments (platinum resistant). The purpose of this study is to test the safety of using a new treatment called Integrated Circuit T (ICT) cells (AB-1015 cells) in patients with ovarian cancer. This treatment has not been approved by the Food and Drug Administration. The goal of this study is to calculate the maximum tolerated dose of the AB-1015 cells. T cells are part of the immune system that protect the body from infection and may help fight cancer. The T cells given in this study will come from the patient and will have a genetic circuit/logic gate put in them that makes them able to recognize alkaline phosphatase, germ line/placental (ALPG/P) and mesothelin (MSLN), 2 proteins on the surface of tumor cells. These logic-gated T cells may help the body's immune system identify and kill cancer cells while sparing normal healthy tissues from toxicity. The AB-1015 cells are given intravenously, after completing 3 rounds of conditioning chemotherapy administered over 3 consecutive days. Conditioning chemotherapy prepares the body to receive the AB-1015 cells. If they continue to meet the eligibility criteria, AB-1015 cells will be given to them 2 days after the last conditioning chemotherapy round. A single infusion of the AB-1015 cells will be given to the subject intravenously. After completion of study treatment, patients are followed with serial measurements of safety, tolerability and response. This is a research study to obtain new information that may help people in the future.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: February 2027
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Recurrent, advanced, platinum resistant ovarian, fallopian tube, and primary peritoneal cancer and must have a histological diagnosis of a high-grade serous histology.
• a) Platinum resistant disease is defined as progression of disease within six months of platinum regimen.
• Doubling of cancer antigen 125 (CA-125) level on 2 successive measurements may be considered as meeting the definition of disease progression
• b) Have received at least 2 lines of prior therapy including a platinum-based regimen if eligible and a poly-ADP ribose polymerase (PARP) inhibitor if BRCA1/2 mutated. No more than 3 lines of prior therapy for the treatment of platinum resistant disease is permitted.
• Adequate organ function as per protocol definitions.
• Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1.
• Evaluable disease (dose escalation cohorts) or measurable disease (backfill cohorts) at time of enrollment as per protocol definitions.
• Negative pregnancy test for women of childbearing potential. Women of non-childbearing potential are those who have been surgically sterilized, have medically confirmed ovarian failure, or have not had menses within the past 12 months.

Exclusion Criteria:

• Cytotoxic chemotherapy within 14 days of time of cell collection.
• Cytotoxic chemotherapy within 14 days of starting of conditioning chemotherapy.
• New York Heart Association functional class II-IV cardiovascular disability
• Clinically significant pericardial effusion
• Pleural or peritoneal effusion that requires drainage for symptom management within 28 days of screening.
• Active autoimmune disease requiring immunosuppressive therapy or uncontrolled with treatment.
• Untreated brain metastasis.
• Subjects unwilling to participate in an extended safety monitoring period.

Related Conditions & MeSH terms

• Abdominal Neoplasm
• Abdominal Neoplasms
• Carcinoma, Ovarian Epithelial
• Fallopian Tube Neoplasms
• Genital Neoplasm, Female
• Genital Neoplasms, Female
• Neoplasms
• Neoplasms, Glandular and Epithelial
• Ovarian Diseases
• Ovarian Neoplasms
• Peritoneal Neoplasms
• Recurrence

Intervention

Biological:
• AB-1015
autologous T cell therapy

Locations

Country	Name	City	State
United States	U of Colorado Cancer Center - Anschutz Medical Campus	Aurora	Colorado
United States	Roswell Park Comprehensive Cancer Center	Buffalo	New York
United States	U of Chicago Comprehensive Cancer Center	Chicago	Illinois
United States	Barbara Ann Karmanos Cancer Institute	Detroit	Michigan
United States	MD Anderson Cancer Center	Houston	Texas
United States	U of Iowa Health Care	Iowa City	Iowa
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	U of Oklahoma, Stephenson Cancer Center	Oklahoma City	Oklahoma
United States	UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco	California
United States	U of Washington - Fred Hutchinson Cancer Center	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Arsenal Biosciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events and dose limiting toxicities (DLTs)	Toxicity grading will be evaluated according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events version 5.0 and monitoring of adverse events. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) events will be graded according to the criteria outlined in the protocol.	Up to 2 years post treatment
Primary	Maximal tolerated dose of AB-1015	Will be determined by a 3x3 dose escalation study	Up to 21 days
Secondary	Number of AB-1015 cells	Number of AB-1015 cells present in patients treatment with AB-1015	Up to 1 year post treatment
Secondary	Evidence of anti-tumor activity	Assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1	Up to 2 years post treatment
Secondary	Co-expression of ALPG and MSLN targets on tumor cells	Assessment by immunohistochemistry (or similar method)	Up to 2 years post treatment